The following studies have contributed to our Cocaine Dependence datasets.
Study 07 – An Introduction to the Family Study of Cocaine
Investigator: Laura Bierut Status: Available at NIDA Abstract: The Family Study of Cocaine Dependence is a 5-year case control study. The study will examine familial and non-familial antecedents and consequences associated with cocaine dependence. This study will allow the identification of social, psychological, and other familial and non-familial factors that are specific to the risk of cocaine dependence, which may...
Study 13 – Genetics of Cocaine Induced Psychosis
Investigator: Joseph F. Cubells Status: Available at NIDA Abstract: (Adapted from applicant's abstract) Cocaine-induced paranoia and psychotic symptoms (CIPPS) are associated with violence and greater morbidity in cocaine users. Since the phenotype appears only after chronic cocaine use, CIPPS provides a direct human example of cocaine-induced sensitization, an understanding of which is critical to addiction sciean in those merely meeting...
Study 29 – Genetics Protocol of the Cocaine Use Reduction with Buprenorphine (CURB) Study; CTN-0048
Investigators: David A. Nielsen, Ph.D., Thomas R. Kosten, M.D. (Baylor College of Medicine), Walter Ling, M.D. (UCLA) Release Date: TBA Abstract: Not available View Study in Clinical Trials Network Site Files No instrument available
Study 30 – Phase 2: Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Nepicastat for Cocaine Dependence
Investigators: Thomas R. Kosten, M.D. (Baylor College of Medicine), Eugene Somoza, M.D., Ph.D., Thomas P. Beresford, M.D., Ph.D. (Cincinnati VA Medical Center), Thomas P. Beresford, M.D. (University of Pennsylvania), Marc Fishman, M.D. (Mountain Manor Treatment Center), Sandra C. Lapham, M.D. (Pacific Institute for Research & Education), Daniel George, MPH (Matrix Institute on Addictions), Frances Levin, M.D. (Columbia University), Christopher J....
Study 44 – Randomized, Placebo-Controlled Trial of Injectable Naltrexone and Monthly Injectable Buprenorphine for Cocaine Use Disorder (CURB-2); CTN-0109
Principal Investigators: Madhukar H. Trivedi, M.D. (University of Texas Southwestern Medical Center), Steve Shoptaw, Ph.D. (University of California, Los Angeles) Site Investigators: Niranjan Karnik, Ph.D. (University of Illinois, Chicago), Gavin Bart, M.D., Ph.D. (Hennepin Healthcare), Sidarth Wakhlu, M.D. (University of Texas Southwestern Medical Center), Marc Fishman, M.D. (Mountain Manor, Baltimore), Jennifer Papac, M.D. (UT Health San Antonio), Venkat Muvva, M.D....